Electra Therapeutics’ IPO cash will support a potential first-in-class drug whose lead indication is a rare hyperinflammatory disorder with no FDA-approved treatments. Meanwhile, clinical-stage biotechs Marea Therapeutics and Sensorion revealed their respective plans to enter the U.S. public markets.
The post Electra’s Upsized IPO Lands $350M for New Class of Precision Immunology Drugs appeared first on MedCity News.
